Teva's stock is a speculative buy with potential upside if biosimilars succeed, but risks remain high due to debt and ...

NEW YORK CITY, NY / ACCESS Newswire / February 28, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential ...

As an enterprise engaged in the development, manufacturing and commercialization of specialty plasma-derived therapeutics, ...

Israeli drug manufacturer Teva Pharmaceutical Industries has resumed the deliveries of the scarce epilepsy drug Finlepsin ...

Teva Pharmaceutical Industries Ltd.'s bid to dismiss antitrust claims should be denied in a case where Mylan Pharmaceuticals Inc. alleges the company unlawfully delayed a generic version of a multiple ...

In high-income countries, more than 80% of children diagnosed with cancer will survive. Yet in some low- and middle-income ...

Catalyst Pharmaceuticals Inc (CPRX) reports a robust 28.3% revenue increase in Q4 2024, driven by strong product performance ...

Amneal Pharmaceuticals, Inc. ( NASDAQ: AMRX) Q4 2024 Earnings Conference Call February 28, 2025 8:30 AM ET ...

Stanley Druckenmiller is a retired hedge fund manager of Duquesne Capital, which focuses on macro investment strategy. His fund constantly delivered high returns, and in 2010, when the fund failed to ...

The company is leaning on its subcutaneous technology to deliver long-acting options that could prevent patients from cycling through drugs.

Tom Hughes is the founder and CEO of Virtual Science AI.

The global generic oncology drugs market is set for consistent growth over the next decade, with sales anticipated to rise from USD 23,743.5 million in 2025 to USD 30,606.3 million by 2035, reflecting ...